Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
about
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerStroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.Patient-derived xenografts: a relevant preclinical model for drug developmentThe promise and challenge of ovarian cancer models.Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methodsIncreased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedinHuman lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivityA VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma.Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDXGenome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging.Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer.Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.Orthotopic Model of Ovarian Cancer.A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenograftsThe latest animal models of ovarian cancer for novel drug discovery.Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models.Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.Recent Insights into Mucinous Ovarian Carcinoma.Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response
P2860
Q26780387-2C2384D5-83CE-45A8-8276-EE91ED0EC8B2Q27307642-0226579D-86E7-4939-87FC-13A27D31094BQ28067191-DA994ADA-3096-4E4D-AF85-0F5207389B25Q35771750-9AABF1FC-073A-4AE9-ACD2-660513B63841Q36123789-C8EA8531-697B-46C3-95DD-B1113E066B00Q36432104-8D10674A-B262-48BA-9888-E85D16FC86A1Q36634788-59318EDF-247B-439F-9E0B-92D9697B30AAQ37157371-CDEC112B-E9B6-400D-8179-51A3FACE9206Q37272622-738559D8-1599-428C-ABEC-1680CE18FF4EQ37295618-74173ABD-E838-4E79-B2EB-28DA639B737BQ37346174-361C6BC1-A9DA-4A68-BC2D-72938908D9EAQ37353774-343EFDFA-5189-4602-9B13-6688EBB275AFQ37522770-564CD28B-B112-4534-9D4B-4C84FCB1B72EQ37702541-76EBEE40-D6C9-4D88-97E7-EBF29E442C08Q37739177-91211F97-4E49-4E80-A248-678875910408Q38605020-AF515189-1199-4398-AC08-7702F5B02B55Q38722976-5BC08B01-44C6-4E27-A7AD-D5478205C688Q39028384-68BB04C5-39C5-4FB0-850F-ABC2A5BFB587Q39178435-F1C67ACA-7552-471E-9E31-3C79E57E5A8BQ41612110-D6277F26-2B95-480F-808B-DDCCE8783500Q41621110-DB839C17-8929-408E-9231-8F41B74F494AQ42344756-AB9CEA0E-E604-4565-B3F4-D707F05B53DBQ47553013-8920B327-6856-47CC-89EA-0E232E4C28A2Q48124146-731E36F5-4895-4692-8E01-62E56FE25502Q48569329-E1787B0E-4F84-4B0A-AF50-927C1FDE2F12Q53421812-82CACFA1-3A20-4336-9B03-9862C8C6DE73Q53518575-D21BDDB9-6D83-4DEA-B383-EEAD9B8758C4Q55181360-F5002C2E-A826-413D-B1E1-68B60A7043B4Q55609057-3BAE4B0A-7139-4078-ACB4-4AB24329883FQ58694894-FA86A2D1-4D04-4A41-9442-04AD848BA26C
P2860
Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
description
im Oktober 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 10 October 2014
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2014
@uk
name
Patient-Derived Ovarian Tumor ...... hology and Genetic Alterations
@en
Patient-Derived Ovarian Tumor ...... hology and Genetic Alterations
@nl
type
label
Patient-Derived Ovarian Tumor ...... hology and Genetic Alterations
@en
Patient-Derived Ovarian Tumor ...... hology and Genetic Alterations
@nl
prefLabel
Patient-Derived Ovarian Tumor ...... hology and Genetic Alterations
@en
Patient-Derived Ovarian Tumor ...... hology and Genetic Alterations
@nl
P2093
P50
P1433
P1476
Patient-derived ovarian tumor ...... hology and genetic alterations
@en
P2093
Alessandro Buda
Federica Guffanti
Francesca Bizzaro
Giovanna Damia
Maria Rosa Bani
Marta Cesca
Paola Ostano
Patrizia Perego
Rodolfo Milani
P304
P356
10.1158/0008-5472.CAN-14-0274
P407
P50
P577
2014-10-10T00:00:00Z